635P Avelumab (AVE) combined with cetuximab (CET) and irinotecan (IRI) for the treatment of refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC): The AVETUXIRI phase II study

Van den Eynde, Marc;Huyghe, Nicolas;Sinapi, Isabelle;De Cuyper, Astrid;Carrasco, Javier;et.al.
(2023) ESMO Congress 2023 — Location: (Spain) Madrid (20.October.2023)

Files

2023_van_den_Eynde_ESMO_635P.pdf
  • Open Access
  • Adobe PDF
  • 95.39 KB
Download

Details

Authors
Show more
Abstract
BACKGROUND : Cetuximab could mediate, independently from RAS mutation, an immunogenic tumor cell death and antitumor immune response. This trial explores the efficacy and safety of AVE, CET and IRI for the treatment of refractory MSS mCRC. [...]
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Van den Eynde, M., Huyghe, N., Sinapi, I., De Cuyper, A., Verstraelen, E., Goffette, P., Ghaye, B., Papier, M., Bedognetti, D., van Maanen, A., Castella, M.-L., Galon, J., & Carrasco, J. (2023). 635P Avelumab (AVE) combined with cetuximab (CET) and irinotecan (IRI) for the treatment of refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC): The AVETUXIRI phase II study. Annals of Oncology, 34(Suppl 1), S450. https://doi.org/10.1016/j.annonc.2023.09.1825 (Original work published 2023)